<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; sans</title>
	<atom:link href="http://www.tapanray.in/tag/sans/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>New Clinical Trial Regime Deserves Support, Sans Threats</title>
		<link>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-clinical-trial-regime-deserves-support-sans-threats</link>
		<comments>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/#comments</comments>
		<pubDate>Thu, 30 Jan 2014 11:19:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[59th]]></category>
		<category><![CDATA[CAC]]></category>
		<category><![CDATA[catalytic]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[sans]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[threats]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4943</guid>
		<description><![CDATA[Recent Supreme Court intervention compelling the Union Government to enforce stringent regulations both for approval and conduct of Clinical Trials (CT) in India, has unfortunately met with some strong resistance with stronger words. Some of these voices are from credible &#8230; <a href="http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug, Patent and Hype: Quo Vadis Pharma Innovation?</title>
		<link>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-patent-and-hype-quo-vadis-pharma-innovation</link>
		<comments>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/#comments</comments>
		<pubDate>Sun, 20 Oct 2013 18:30:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[discover]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[Hype]]></category>
		<category><![CDATA[indications]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[Nature]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patentable]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Prescire]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Reviews]]></category>
		<category><![CDATA[sans]]></category>
		<category><![CDATA[Section(3d)]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2704</guid>
		<description><![CDATA[A recent research report reveals, though the pharmaceutical companies in the United States since mid 2000 have spent over US$ 50 billion every year to discover new drugs, they have very rarely been able to invent something, which can be called significant &#8230; <a href="http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
